Precigen (NASDAQ:PGEN) Given New $9.00 Price Target at Citizens Jmp

Precigen (NASDAQ:PGEN) had its price objective raised by Citizens Jmp from $8.00 to $9.00 in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has a market outperform rating on the biotechnology company’s stock.

Other research analysts have also issued research reports about the company. Zacks Research raised Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. HC Wainwright increased their price target on Precigen from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.50.

Precigen Stock Performance

NASDAQ PGEN opened at $3.89 on Thursday. The company has a quick ratio of 3.95, a current ratio of 4.04 and a debt-to-equity ratio of 2.22. Precigen has a 52-week low of $1.11 and a 52-week high of $5.47. The business’s 50-day moving average price is $4.10 and its 200 day moving average price is $3.98. The firm has a market cap of $1.37 billion, a P/E ratio of -2.90 and a beta of 1.10.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.09. The firm had revenue of $4.57 million for the quarter, compared to analysts’ expectations of $8.29 million. Precigen had a negative return on equity of 2,313.82% and a negative net margin of 2,588.21%. On average, equities research analysts expect that Precigen will post -0.32 earnings per share for the current year.

Hedge Funds Weigh In On Precigen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Patient Capital Management LLC lifted its holdings in shares of Precigen by 62.6% in the 3rd quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company’s stock valued at $87,056,000 after buying an additional 10,192,107 shares during the period. State Street Corp boosted its stake in shares of Precigen by 141.1% in the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock valued at $45,248,000 after buying an additional 6,335,033 shares in the last quarter. SymBiosis Capital Partners LLC acquired a new position in Precigen during the fourth quarter worth $12,540,000. Bank of America Corp DE grew its holdings in Precigen by 201.1% during the third quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock worth $8,245,000 after acquiring an additional 1,673,731 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in Precigen by 196.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,173,933 shares of the biotechnology company’s stock worth $9,087,000 after acquiring an additional 1,440,446 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

More Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: PAPZIMEOS commercial momentum — Precigen reports accelerating U.S. launch demand, broad payer coverage and expects Q1 revenue to exceed $18M (company guidance), supporting a rising near‑term revenue run‑rate. Precigen expects Q1 revenue to exceed $18M
• Positive Sentiment: CMS coding and access tailwind — A permanent J‑code (J3404) for PAPZIMEOS effective April 1 will streamline claims and likely improve reimbursement/uptake. This is a direct commercial enabler for sustained sales growth. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms raised targets/ratings (Citizens JMP to $9, HC Wainwright to $10), signaling stronger sell‑side conviction around commercial upside and valuation re‑rating. Benzinga price target coverage
• Positive Sentiment: Cash runway and breakeven plan — Management reports ~$100.4M in cash and expects operations to reach cash‑flow breakeven in 2026, reducing near‑term financing risk. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Neutral Sentiment: Analyst valuation note — A recent Seeking Alpha piece models scenario‑weighted fair value around $6.13 (base case ~$7.01), highlighting upside versus current levels but dependent on sustained commercial execution. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Regulatory/clinical updates — EMA validated an MAA for PAPZIMEOS and an open‑label redosing study was initiated; these are medium‑term positives but will take time to materially affect revenue. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Negative Sentiment: Mixed Q4 results — EPS slightly beat expectations (reported roughly breakeven per share vs. a larger expected loss), but product/total revenue of ~$4.57M missed consensus (~$8.3M), showing launch sales still ramping and generating near‑term volatility in reported numbers. PGEN Q4 earnings summary
• Negative Sentiment: Short‑term execution risk — Revenue is still concentrated on an early launch with payer rollout timing and demand variability; missed revenue estimates underscore execution risk that could pressure the stock if quarterly cadence disappoints. Zacks: Precigen Reports Q4 Loss, Lags Revenue Estimates

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.